AU2012278744B2 - Use of Salmonella flagellin derivative in preparation of drug for preventing and treating inflammatory bowel diseases - Google Patents

Use of Salmonella flagellin derivative in preparation of drug for preventing and treating inflammatory bowel diseases Download PDF

Info

Publication number
AU2012278744B2
AU2012278744B2 AU2012278744A AU2012278744A AU2012278744B2 AU 2012278744 B2 AU2012278744 B2 AU 2012278744B2 AU 2012278744 A AU2012278744 A AU 2012278744A AU 2012278744 A AU2012278744 A AU 2012278744A AU 2012278744 B2 AU2012278744 B2 AU 2012278744B2
Authority
AU
Australia
Prior art keywords
czlc331
dosage form
protein
treatment
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012278744A
Other languages
English (en)
Other versions
AU2012278744A1 (en
Inventor
Yan Gao
Junhuai LI
Weiguang Li
Zhihui Li
Yonghong Wu
Yang Xu
Chenggang Zhang
Yanchun ZHANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Sciscape Biomedicine Science & Technology Co Ltd
Institute of Radiation Medicine of CAMMS
Original Assignee
Suzhou Sciscape Biomedicine Science & Tech Co Ltd
Institute of Radiation Medicine of CAMMS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Sciscape Biomedicine Science & Tech Co Ltd, Institute of Radiation Medicine of CAMMS filed Critical Suzhou Sciscape Biomedicine Science & Tech Co Ltd
Publication of AU2012278744A1 publication Critical patent/AU2012278744A1/en
Application granted granted Critical
Publication of AU2012278744B2 publication Critical patent/AU2012278744B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2012278744A 2011-07-05 2012-01-19 Use of Salmonella flagellin derivative in preparation of drug for preventing and treating inflammatory bowel diseases Ceased AU2012278744B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201110186065 2011-07-05
CN201110186065.6 2011-07-05
PCT/CN2012/000097 WO2013004069A1 (zh) 2011-07-05 2012-01-19 沙门氏菌鞭毛蛋白衍生物在制备防治炎症性肠病药物中的应用

Publications (2)

Publication Number Publication Date
AU2012278744A1 AU2012278744A1 (en) 2014-02-20
AU2012278744B2 true AU2012278744B2 (en) 2016-11-24

Family

ID=47436474

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012278744A Ceased AU2012278744B2 (en) 2011-07-05 2012-01-19 Use of Salmonella flagellin derivative in preparation of drug for preventing and treating inflammatory bowel diseases

Country Status (8)

Country Link
US (2) US9259453B2 (enExample)
EP (1) EP2730287B1 (enExample)
JP (1) JP5876930B2 (enExample)
KR (1) KR101814558B1 (enExample)
CN (1) CN102861317B (enExample)
AU (1) AU2012278744B2 (enExample)
CA (1) CA2840924A1 (enExample)
WO (1) WO2013004069A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11273198B2 (en) 2017-05-04 2022-03-15 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders
US10402165B2 (en) 2017-08-30 2019-09-03 Gsi Technology Inc. Concurrent multi-bit adder
CN108159397A (zh) * 2018-02-28 2018-06-15 中南大学湘雅三医院 一种肠罗斯氏菌重组鞭毛蛋白在制备防治炎症性肠病药物中的应用
CN108404113A (zh) * 2018-05-16 2018-08-17 中国人民解放军军事科学院军事医学研究院 用于抗辐射损伤的口服辐抗肽药物组合物
US20220218786A1 (en) * 2019-03-28 2022-07-14 The Catholic University Of Korea Industry-Academic Cooperation Foundation Composition for preventing or treating graft-versus-host disease comprising tlr5 agonist derived from flagellin as effective component
CN110420317B (zh) * 2019-07-25 2022-11-22 中国人民解放军军事科学院军事医学研究院 Cblb502蛋白在防治创伤后应激障碍中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1841785A2 (en) * 2005-01-19 2007-10-10 Vaxinnate Corporation Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050073865A (ko) * 2004-01-12 2005-07-18 대한민국(전남대학교총장) 비브리오 패혈증균 편모 구성인자 플라젤린을유효성분으로 함유하는 백신 보조제
JP5285278B2 (ja) * 2004-12-22 2013-09-11 クリーブランド クリニック ファウンデイション フラゲリン関連ポリペプチドおよびその使用
CA2531261A1 (en) * 2005-12-21 2007-06-21 Institut Pasteur Control of intestinal inflammatory syndromes with a preparation of killed or non infectious bacteria
JP2011519834A (ja) * 2008-04-25 2011-07-14 インスティチュート フォー システムズ バイオロジー フラジェリンポリペプチドワクチン
CN101411872A (zh) * 2008-11-25 2009-04-22 中国科学院武汉病毒研究所 预防龋齿的疫苗试剂盒及其使用方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1841785A2 (en) * 2005-01-19 2007-10-10 Vaxinnate Corporation Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response

Also Published As

Publication number Publication date
KR20140054018A (ko) 2014-05-08
EP2730287B1 (en) 2018-02-28
JP2014522819A (ja) 2014-09-08
US9630999B2 (en) 2017-04-25
NZ619871A (en) 2016-02-26
US20140248348A1 (en) 2014-09-04
WO2013004069A1 (zh) 2013-01-10
CN102861317B (zh) 2014-07-02
EP2730287A4 (en) 2015-03-18
AU2012278744A1 (en) 2014-02-20
US20160060305A1 (en) 2016-03-03
KR101814558B1 (ko) 2018-01-30
EP2730287A1 (en) 2014-05-14
JP5876930B2 (ja) 2016-03-02
US9259453B2 (en) 2016-02-16
CN102861317A (zh) 2013-01-09
CA2840924A1 (en) 2013-01-10

Similar Documents

Publication Publication Date Title
US9630999B2 (en) Use of Salmonella flagellin derivative in preparation of drug for preventing and treating inflammatory bowel diseases
JP2025163025A (ja) 糖尿病、高血圧および高コレステロール血症を治療するための組成物および方法
EP2686431A1 (en) Antagonists of the interleukin- 1 receptor
CN105753963B (zh) 高活性艾塞那肽类似物及其医药应用
WO2015010615A1 (zh) 一种重组trail蛋白及其制备方法和用途
WO2021204170A1 (zh) 一种中华冀土鳖虫来源的具有降血脂功能的活性肽及其制备方法和应用
JP6757667B2 (ja) Ｃｄ２８を介したシグナル伝達を阻害する短ペプチドによる炎症性疾病の症候の軽減
CN109718363B (zh) 预防、缓解或治疗阿尔茨海默病的肽及其应用
WO2016078549A1 (zh) 一种肿瘤血管梗塞剂多肽、基因、表达载体及其应用
AU2020234373B2 (en) Novel peptide and use thereof
JP5225393B2 (ja) 水溶性高分子修飾ｇ−ｃｓｆ複合体
JP4744443B2 (ja) 毒素中和性ペプチドのスクリーニング方法とｓｔｘ２阻害性ペプチド並びにベロ毒素中和剤
NZ619871B2 (en) Use of salmonella flagellin derivative in preparation of drug for preventing and treating inflammatory bowel diseases
CN102295683B (zh) 抗单纯疱疹病毒多肽及其应用
CN114668843A (zh) 一种纳米自组装糖肽biva-pk及其在缺血再灌注损伤导致的肾脏纤维化中的应用
CN110420317B (zh) Cblb502蛋白在防治创伤后应激障碍中的应用
CN111732631B (zh) 一种多肽及其在制备治疗和预防肿瘤的药物中的应用
CN113941000A (zh) Akap1蛋白作为治疗代谢相关疾病的药物靶点的应用及方法
CN116732006B (zh) 副溶血弧菌噬菌体解聚酶及其应用
WO2024259977A1 (zh) 经修饰的多肽及其在镇痛领域的应用
EP4154899A1 (en) Drug with prolonged analgesic action
TWI328011B (en) Recombinant super-compound interferon
KR101917419B1 (ko) Ｃｒｉｆ１을 유효성분으로 포함하는 자가면역질환의 예방 또는 치료용 조성물
CN120324579A (zh) 嵌合多肽TAT-Ae单独或联合AKT抑制剂在治疗肿瘤中的应用
CN116284232A (zh) 用于治疗囊状幼虫病病毒感染的多肽、药物组合物与应用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired